ID: ALA285518

Max Phase: Preclinical

Molecular Formula: C22H33N3O5S

Molecular Weight: 451.59

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC=O

Standard InChI:  InChI=1S/C22H33N3O5S/c1-15(2)12-18(24-20(27)17(23-14-26)10-11-31-4)21(28)25-19(22(29)30-3)13-16-8-6-5-7-9-16/h5-9,14-15,17-19H,10-13H2,1-4H3,(H,23,26)(H,24,27)(H,25,28)/t17-,18-,19-/m0/s1

Standard InChI Key:  FTDSTRQDCPIBEG-FHWLQOOXSA-N

Associated Targets(Human)

Superoxide dismutase 173 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Homo sapiens 32628 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

P-glycoprotein 1 14716 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

fMet-Leu-Phe receptor 1/2 66 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Lysozyme C 11 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 451.59Molecular Weight (Monoisotopic): 451.2141AlogP: 1.29#Rotatable Bonds: 14
Polar Surface Area: 113.60Molecular Species: NEUTRALHBA: 6HBD: 3
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.06CX Basic pKa: CX LogP: 1.83CX LogD: 1.83
Aromatic Rings: 1Heavy Atoms: 31QED Weighted: 0.29Np Likeness Score: -0.16

References

1. Cavicchioni G, Vertuani G, Scatturin A, Spisani S.  (1994)  The role of peptide bond in chemotactic for-met-leu-phe-ome focused by depsipeptide analogs,  (13): [10.1016/S0960-894X(01)80564-3]
2. Cavicchioni G, Turchetti M, Spisani S..  (2001)  Biological activity in human neutrophils of di-tripeptides, analogues of the chemotactic fMLP.,  11  (24): [PMID:11720864] [10.1016/s0960-894x(01)00640-0]
3. Torino D, Mollica A, Pinnen F, Feliciani F, Spisani S, Lucente G..  (2009)  Novel chemotactic For-Met-Leu-Phe-OMe (fMLF-OMe) analogues based on met residue replacement by 4-amino-proline scaffold: synthesis and bioactivity.,  17  (1): [PMID:19081258] [10.1016/j.bmc.2008.11.010]
4. Cavicchioni G, Fraulini A, Falzarano S, Spisani S..  (2009)  Oligomeric formylpeptide activity on human neutrophils.,  44  (12): [PMID:19748709] [10.1016/j.ejmech.2009.08.010]
5. Borgnia MJ, Eytan GD, Assaraf YG..  (1996)  Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity.,  271  (1): [PMID:8621716] [10.1074/jbc.271.6.3163]
6. Hayashi R, Miyazaki M, Osada S, Kawasaki H, Fujita I, Hamasaki Y, Kodama H..  (2013)  A formyl peptide substituted with a conformationally constrained phenylalanine residue evokes a selective immune response in human neutrophils.,  21  (3): [PMID:23276447] [10.1016/j.bmc.2012.11.046]